Pneumonia — Clinical Documentation Guide (2026)

This Clinical Documentation Guide (CDG) provides AAPC/AHIMA-credentialed coders and CDI specialists with comprehensive coding, clinical, and documentation guidance for pneumonia across all organism types and care settings. Content reflects FY2026 ICD-10-CM guidelines (effective October 1, 2025 – September 30, 2026) and incorporates the most current clinical, reimbursement, and HCC risk-adjustment resources. Use this guide to ensure accurate diagnosis code assignment, appropriate organism-level specificity, CDI query triggers, and defensible documentation for pneumonia encounters across inpatient and outpatient settings.

🔍 1. Definition

Pneumonia is an acute infection of the lung parenchyma — the alveoli and surrounding interstitium — causing inflammation and fluid or purulent exudate that impairs gas exchange. According to the National Heart, Lung, and Blood Institute (NHLBI), pneumonia can be caused by bacteria, viruses, fungi, or other organisms, and severity ranges from mild outpatient illness to life-threatening respiratory failure requiring mechanical ventilation.

From an ICD-10-CM coding perspective, pneumonia is not a single condition but rather a category of infections classified by organism specificity (the primary coding determinant), site within the lung, care setting of acquisition (community-acquired vs. hospital-acquired vs. ventilator-associated), and aspiration mechanism. The FY2026 ICD-10-CM Tabular List classifies most pneumonias within Chapter 10 (Diseases of the Respiratory System, J00–J99), with additional codes in Chapter 1 (Infectious/Parasitic Diseases) when the causative organism is separately indexed.

Epidemiology: Pneumonia is one of the leading causes of hospitalization in the United States. The CDC reports that approximately 1.5 million Americans are hospitalized for pneumonia annually, with over 40,000 deaths per year. Community-acquired pneumonia (CAP) accounts for the majority of episodes; hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) carry substantially higher mortality and resource utilization.

Pneumonia by Acquisition Setting

• Community-Acquired Pneumonia (CAP): Develops outside the hospital or within 48 hours of admission in a patient not previously hospitalized; most common organisms are Streptococcus pneumoniae, Mycoplasma pneumoniae, respiratory viruses, and Legionella.
• Hospital-Acquired Pneumonia (HAP): Develops ≥48 hours after hospital admission, not incubating at admission; gram-negative bacilli and Staphylococcus aureus predominate per IDSA guidelines.
• Ventilator-Associated Pneumonia (VAP): A subset of HAP occurring in mechanically ventilated patients; coded J95.851 per FY2026 ICD-10-CM.
• Aspiration Pneumonia: Results from inhalation of oropharyngeal or gastric contents; coded J69.0 and carries HCC 280 (~0.329 RAF) under CMS-HCC Model v28.

🗂️ 2. Alternative Terminology

Coders and CDI specialists will encounter many terms in provider documentation that map to specific pneumonia codes. Understanding equivalent terminology is critical for accurate code assignment.

🩺 3. Signs & Symptoms

Clinical presentation guides both diagnosis and documentation specificity. CDI specialists should review the chart for these findings to support organism-level query triggers per ACDIS CDI practice standards:

Classic Symptoms

• Productive cough (purulent sputum in bacterial; scant in atypical/viral)
• Fever (temperature >38.0°C / 100.4°F) with or without chills/rigors
• Dyspnea and increased respiratory rate (tachypnea)
• Pleuritic chest pain (sharp, worse with inspiration — suggests lobar involvement)
• Hypoxemia (SpO₂ <94% or PaO₂/FiO₂ ratio <300 in severe cases)
• Malaise, fatigue, anorexia
• Altered mental status (especially in elderly — an underrecognized presentation)

Physical Examination Findings

• Tachycardia, tachypnea, hypotension (in sepsis/severe cases)
• Bronchial breath sounds, dullness to percussion over consolidation
• Egophony ("E to A" change), whispered pectoriloquy
• Crackles/rales on auscultation
• Decreased breath sounds (pleural effusion)

Diagnostic Findings Driving Code Specificity

• Chest X-ray / CT scan: Lobar consolidation, interstitial infiltrates, ground-glass opacities
• Gram stain and culture: Most important for organism specificity; coders should query when gram stain documents organism class but attending diagnosis is "pneumonia, unspecified"
• Blood cultures: Positive cultures shift coding to bacteremic pneumonia ± sepsis (A40.x/A41.x)
• Sputum culture: Organism-level identification enables J13–J16 vs. J18.9
• Urinary antigen tests: Streptococcus pneumoniae and Legionella antigens
• Respiratory PCR panels: Influenza A/B, RSV, SARS-CoV-2, hMPV, parainfluenza
• Procalcitonin / WBC: Supports bacterial vs. viral distinction for CDI query
• Bronchoscopy/BAL cultures: Key for VAP and immunocompromised patients

🧭 4. Differential Diagnosis

Accurate coding requires distinguishing pneumonia from conditions that may mimic it radiographically or clinically. The following differential diagnoses are relevant for coders and CDI specialists when validating provider documentation:

📋 5. Clinical Indicators for Coders/CDI

The following table maps documentation elements to their coding impact, supporting accurate code assignment and meaningful CDI queries per AHIMA coding standards:

🦴 6. Anatomy & Pathophysiology

Understanding the pathophysiology of pneumonia is essential for coding accuracy and query formulation. The lower respiratory tract — below the vocal cords — includes the trachea, bronchi, bronchioles, alveolar ducts, and alveoli. Pneumonia specifically involves the alveolar and interstitial compartments, as described by NHLBI.

Pathophysiologic Mechanisms by Organism Class

• Bacterial pneumonia: Organisms (e.g., S. pneumoniae, Klebsiella) colonize the lower airways and trigger an intense neutrophilic inflammatory response. Alveolar exudate (lobar consolidation) impairs gas exchange. Bacteremia and sepsis can ensue when organisms breach the alveolar-capillary barrier.
• Atypical bacterial pneumonia: Organisms such as Mycoplasma pneumoniae, Chlamydophila pneumoniae, and Legionella pneumophila cause predominantly interstitial inflammation with less alveolar exudate — hence the "atypical" presentation with scant productive cough and often normal initial CXR.
• Viral pneumonia: Viruses (influenza, RSV, SARS-CoV-2) infect type I and II pneumocytes directly, triggering cytokine-mediated inflammatory cascades. COVID-19 pneumonia (U07.1 + J12.82) may progress to diffuse alveolar damage (DAD) and ARDS.
• Fungal pneumonia: Occurs primarily in immunocompromised hosts. Pneumocystis jirovecii (B59) attaches to type I pneumocytes causing alveolar flooding; Aspergillus (B44) invades vascular structures causing hemorrhagic infarction.
• Aspiration pneumonia: Aspiration of oropharyngeal bacteria-laden secretions or gastric contents triggers an anaerobic bacterial infection (J69.0) or, with sterile gastric acid, a chemical pneumonitis (J68.0). Risk factors include dysphagia, altered mental status, seizures, and nasogastric tube use.

HAP/VAP Pathophysiology

Hospital-acquired organisms colonize the oropharynx and, through microaspiration, reach the lower airways. In mechanically ventilated patients, the endotracheal tube bypasses natural airway defenses; VAP (J95.851) develops when these hospital-acquired organisms (commonly Pseudomonas aeruginosa, Acinetobacter, MRSA) establish infection per IDSA HAP/VAP guidelines.

💊 7. Medication Impact / Treatment

Medication documentation is a critical component of clinical validation for pneumonia coding. Treatment regimen supports — and sometimes establishes — organism type for CDI query purposes. According to IDSA CAP guidelines (2019, updated 2024):

Antibiotic Treatment by Organism / Setting

• CAP (outpatient, mild): Amoxicillin or doxycycline for typical organisms; azithromycin/doxycycline for atypical
• CAP (inpatient, non-ICU): Beta-lactam + macrolide (e.g., ceftriaxone + azithromycin) or respiratory fluoroquinolone (levofloxacin, moxifloxacin); HCPCS J0696 (ceftriaxone), J0744 (ciprofloxacin)
• CAP (ICU/severe): Beta-lactam + macrolide or fluoroquinolone; add anti-MRSA coverage (vancomycin, linezolid) if risk factors present
• HAP/VAP: Broad-spectrum anti-pseudomonal coverage — piperacillin-tazobactam (J2543), cefepime, meropenem ± vancomycin/linezolid per IDSA HAP/VAP guidelines; ceftolozane-tazobactam (J0695) for MDR Pseudomonas
• Aspiration pneumonia: Anaerobic coverage (ampicillin-sulbactam, clindamycin, metronidazole); aspirated sterile acid (pneumonitis) may not require antibiotics initially
• MRSA pneumonia: Vancomycin or linezolid; treatment of MRSA supports J15.212 query
• Fungal pneumonia (PCP): TMP-SMX (Bactrim) — first-line for Pneumocystis jirovecii (B59); pentamidine IV (J2545) for sulfa allergy
• Viral (influenza): Oseltamivir (Tamiflu — PO, J3535 not applicable for IV; note J3535 is oral agent, separate billing); J10.00/J10.01/J09.X1 depending on confirmed type
• COVID-19 pneumonia: Remdesivir, dexamethasone, supplemental oxygen; U07.1 + J12.82 coding; severity drives DRG assignment

Supportive and Respiratory Treatments

• Supplemental oxygen / high-flow nasal cannula (HFNC)
• Nebulized bronchodilators: albuterol/ipratropium (J7621, CPT 94640)
• CPAP / BiPAP for hypoxic respiratory failure (CPT 94660); codes J96.0x if respiratory failure documented
• Mechanical ventilation: codes J95.851 VAP if pneumonia develops after intubation; Z99.11 ventilator dependence if chronic
• Corticosteroids: dexamethasone in severe CAP/COVID pneumonia and for PCP/PJP with hypoxemia

Preview ends here. The full guide continues with FY2026 ICD-10-CM code sets, CPT surgical coding, MS-DRG mapping, reimbursement guidance, CDI query templates, and an audit checklist — all available to CCO Members.

← Back to All Clinical Documentation Guides